Acotiamide Treatment for Functional Dyspepsia

Clinical Positioning and Dosing

The British Society of Gastroenterology guidelines recommend testing and treating for H. pylori in all patients with dyspepsia, followed by empirical acid suppression with PPIs, and considering prokinetics like acotiamide only after these steps, particularly for postprandial distress syndrome (PDS) symptoms (strong recommendation for the first two steps, high-quality evidence; weak recommendation for prokinetics, low-quality evidence) 1, 2, 3
Acotiamide should be dosed at 100 mg three times daily (TID) for functional dyspepsia, particularly for PDS, with a weak recommendation and low-quality evidence 1, 2, 3
The American Gastroenterological Association is not mentioned, however the British Society of Gastroenterology establishes that acotiamide is not a first-line therapy for functional dyspepsia, and should only be considered after the above steps (weak recommendation, low-quality evidence) 1, 2, 3

If acotiamide fails after 4-8 weeks, advance to tricyclic antidepressants (e.g., amitriptyline 10 mg once daily, titrated to 30-50 mg) as second-line therapy (strong recommendation, moderate-quality evidence) 1, 2, 3, 5
Itopride can be used as an interchangeable first-line prokinetic option, although with weak recommendation and low-quality evidence 5, 6
Tegaserod has stronger evidence (strong recommendation, moderate-quality evidence) but limited availability 1, 2, 3

Acotiamide achieves therapeutic effects through dual mechanisms: muscarinic receptor antagonism and acetylcholinesterase inhibition, although the source of this information is of lower quality 4
The British Society of Gastroenterology rates the evidence for acotiamide as low quality with only a weak recommendation, contrasting with PPIs which have strong recommendations with high-quality evidence 1, 2, 3